Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Health Behaviour Change

Comments on UK spending review

UK's ABPI and BIA comment on the government's commitment to healthcare and life sciences following the Comprehensive Spending Review

DH bodies to be axed

Thirty public bodies related to the UK Department of Health are to be axed or reconstituted as part of government efforts to reform public services

UK government halts generic drug plans

The UK's coalition government has said it has decided not to progress with plans to replace branded drugs with generic medicines in primary care

NICE reverses Alzheimer’s drug stance

Challenging a previous ruling, the UK's health watchdog has recommended Alzheimer's drugs for a wider severity of disease cases in draft guidance

New DH permanent secretary

The Department of Health has appointed Una O'Brien as permanent secretary, with responsibilities including the management of healthcare reforms

NHS reforms face growing criticism

Shadow health secretary condemns 'bad deal' as BMA withdraws support

Quarter of doctors use online network daily

Online network Doctors.net.uk is witnessing record levels of engagement with doctors and has seen more than 40,000 unique users a day

New campaign to promote cancer check-ups

The UK's Department of Health has announced a new campaign to alert people to early signs of cancer and encourage check-ups

Former BMA chair to face disciplinary panel

Former chairman of the British Medical Association, James Johnson, is due to appear before a disciplinary panel accused of professional misconduct

SMC approves Glivec for GIST

Glivec has been approved for use within NHS Scotland as adjuvant post-surgery therapy to delay the recurrence of GIST

SMC approves Multaq, recommends Nexium

The Scottish Medicines Consortium has approved S-A's Multaq for use and issued a positive recommendation on AZ's Nexium sachets for children

Draft NICE guidance rejects GSK’s Revolade

Draft guidance from the UK's NICE has not recommended GSK's Revolade for chronic immune thrombocytopenic purpura

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links